Email Alert RSS
Volume 11 Issue 1
Jan.  2020
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2020  >  11(1): 91-95
Jian-hua DENG, Han-zhong LI. Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 91-95. doi: 10.3969/j.issn.1674-9081.20170164
Citation: Jian-hua DENG, Han-zhong LI. Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(1): 91-95. doi: 10.3969/j.issn.1674-9081.20170164
shu

Diagnosis and Clinical Treatment of Primary Adrenal Lymphoma

doi: 10.3969/j.issn.1674-9081.20170164

  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author: LI Han-zhong Tel: 86-10-69156035, E-mail: lihzhpumch@163.com
  • Received Date: 2019-05-18
  • Publish Date: 2020-01-30
    Abstract
  • The clinical presentation of primary adrenal lymphoma(PAL) is comprised of major general symptoms. Although adrenal insufficiency is very common in patients with bilateral involvement, it has not been systematically tested. Positron emission tomography is an efficient examination to visualize extra-adrenal locations. The preliminary results of magnetic resonance imaging to distinguish between PAL and adrenocortical carcinoma should be confirmed. Further studies are needed to establish an optimal strategy for the management of patients with PAL. At present, it is unclear whether the adjunction of rituximab (R) and CHOP(cyclophosphamide, doxorubicin, vincristine, prednisone) can cure patients with high-risk aggressive lymphoma. It is also unknown whether the prolonged complete response was due to R-CHOP alone. It is necessary to emphasize that early diagnosis of PAL before the appearance of adrenal insufficiency contributes to decreasing the patients' morbidity and mortality.
    • FullText(HTML)
  • loading
    • References(34)
  • [1] Rashidi A, Fisher SI. Primary adrenal lymphoma:a systematic review[J]. Ann Hematol, 2013, 92:1583-1593. doi:  10.1007/s00277-013-1812-3
    [2] Kumar R, Xiu Y, Mavi A, et al. FDG-PET imaging in primary bilateral adrenal lymphoma:a case report and review of the literature[J]. Clin Nucl Med, 2016, 30:222-230. https://www.ncbi.nlm.nih.gov/pubmed/15764875
    [3] Kasaliwal R, Goroshi M, Khadilkar K, et al. Primary Adrenal Lymphoma:A Single-center Experience[J].Endocr Pract, 2015, 21:719-724. doi:  10.4158/EP14471.OR
    [4] Martínez-Esteve A, García-Gómez FJ, Madrigal-Toscano MD, et al. Primary bilateral diffuse large B-cell lymphoma of the adrenals[J]. Br J Haematol, 2015, 170:3. doi:  10.1111/bjh.13466
    [5] Raoofziaee M, Yarmohamadi A, Ahmadnia H.Primary bilateral non-Hodgkin's lymphoma of the adrenal gland[J].Indian J Urol, 2018, 34:300-302. doi:  10.4103/iju.IJU_113_18
    [6] Ohkura Y, Shindoh J, Haruta S, et al. Primary Adrenal Lymphoma Possibly Associated With Epstein-Barr Virus Reactivation Due to Immunosuppression Under Methotrexate Therapy[J]. Medicine, 2015, 94:e1270. doi:  10.1097/MD.0000000000001270
    [7] Mozos A, Ye H, Chuang WY, et al. Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis[J]. Mod Pathol, 2009, 22:1210-1217. doi:  10.1038/modpathol.2009.87
    [8] Grigg AP, Connors JM. Primary adrenal lymphoma[J]. Clin Lymphoma, 2016, 4:154-160. https://www.ncbi.nlm.nih.gov/pubmed/12769357
    [9] Padhi S, Sahoo J. Primary adrenal non Hodgkin lymphoma:changing trends[J]. Turk J Gastroenterol, 2015, 26:85-86. doi:  10.5152/tjg.2015.4882
    [10] Erçolak V, Kara O, Günaldi M, et al. Bilateral primary adrenal non-hodgkin lymphoma[J]. Turk J Haematol, 2014, 31:205-206. doi:  10.4274/tjh.2013.0195
    [11] Robertus JL, Harms G, Blokzijl T, et al. Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma[J]. Mod Pathol, 2009, 22:547-555. doi:  10.1038/modpathol.2009.10
    [12] Nakatsuka S, Hongyo T, Syaifudin M, et al. Mutations of p53, c-kit, K-ras, and beta-catenin gene in non-Hodgkin's lymphoma of adrenal gland[J]. Jpn J Cancer Res, 2002, 93:267-274. doi:  10.1111/j.1349-7006.2002.tb02168.x
    [13] Ide M, Fukushima N, Hisatomi T, et al. Non-germinal cell phenotype and Bcl-2 expression in primary adrenal diffuse large B-cell lymphoma[J]. Leuk Lymphoma, 2007, 48:2244-2246. doi:  10.1080/10428190701636450
    [14] Hong J, Park S, Park J, et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy[J]. Leuk Lymphoma, 2011, 52:1904-1912. doi:  10.3109/10428194.2011.588761
    [15] Hans CP, Weisenburger DD, Greiner TC, et al. Confirma-tion of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103:275-282. doi:  10.1182/blood-2003-05-1545
    [16] Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy[J]. Clin Cancer Res, 2009, 15:5494-5502. doi:  10.1158/1078-0432.CCR-09-0113
    [17] Eyden B, Chakrabarty B, Hatimy U. Carcinoma versus cytokeratin-positive lymphoma:a case report emphasizing the diagnostic role of electron microscopy[J]. Ultrastruct Pathol, 2009, 33:33-38. doi:  10.1080/01913120802625830
    [18] Rashidi A, Bergeron CW, Fisher SI, et al. Primary adrenal de novo CD5-positive diffuse large B-cell lymphoma[J]. Ann Hematol, 2013, 92:1281-1282. doi:  10.1007/s00277-013-1690-8
    [19] Donner LR, Mott FE, Tafur I. Cytokeratin-positive, CD45-negative primary centroblastic lymphoma of the adrenal gland:a potential for a diagnostic pitfall[J]. Arch Pathol Lab Med, 2001, 125:1104-1106. https://www.ncbi.nlm.nih.gov/pubmed/11473470
    [20] Chen P, Jin L, Yang Y, et al. Bilateral primary adrenal diffuse large B cell lymphoma without adrenal insufficiency:A case report and review of the literature[J]. Mol Clin Oncol, 2017, 7:145-147. doi:  10.3892/mco.2017.1264
    [21] Chakrabarti I, Bhowmik S, Sinha MG, et al. Ultrasound-guided aspiration cytology of retroperitoneal masses with histopathological corroboration:A study of 71 cases[J]. J Cytol, 2014, 3115-3119.
    [22] Mehmood S, Jahan A, Loya A, et al. Onsite cytopathology evaluation and ancillary studies beneficial in EUS-FNA of pancreatic, mediastinal, intra-abdominal, and submucosal lesions[J]. Diagn Cytopathol, 2015, 43:278-286. doi:  10.1002/dc.23207
    [23] Guo AC, Cummings TJ, Dash RC. Lymphomas and high-grade astrocytomas:comparison of water diffusibility and histologic characteristics[J]. Radiology, 2002, 224:177-183. doi:  10.1148/radiol.2241010637
    [24] Kuritzkes B, Parikh M, Melamed J, et al. False-positive rate of positron emission tomography/computed tomography for presumed solitary metastatic adrenal disease in patients with known malignancy[J]. Ann Surg Oncol, 2015, 22:437-440. doi:  10.1245/s10434-014-4031-9
    [25] Cistaro A, Niccoli Asabella A, Coppolino P, et al. Diag-nostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies-a multicenter experience[J]. Hell J Nucl Med, 2015, 18:97-102.
    [26] López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma:clinical and biological characteriza-tion and outcome according to the nodal or extranodal primary origin[J]. J Clin Oncol, 2005, 23:2797-2804. doi:  10.1200/JCO.2005.07.155
    [27] Abe R, Ogawa K, Maruyama Y, et al. Spontaneous regression of diffuse large B-cell lymphoma harbouring Epstein-Barr virus:a case report and review of the literature[J]. J Clin Exp Hematop, 2007, 47:23-26. doi:  10.3960/jslrt.47.23
    [28] Marković O, Marisavljević D, Jelić S, et al. Double-hit primary unilateral adrenal lymphoma with good outcome[J]. Vojnosanit Pregl, 2014, 71:689-692. doi:  10.2298/VSP1407689M
    [29] Kim YR, Kim JS, Min YH, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)[J]. J Hematol Oncol, 2012, 5:49. doi:  10.1186/1756-8722-5-49
    [30] Acker SN, Bruny JL, Garrington TP, et al. Minimally invasive surgical techniques are safe in the diagnosis and treatment of pediatric malignancies[J]. Surg Endosc, 2015, 29:1203-1208. doi:  10.1007/s00464-014-3795-0
    [31] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J]. N Engl J Med, 2002, 346:235-242. doi:  10.1056/NEJMoa011795
    [32] Hiemcke-Jiwa LS, Leguit RJ, Radersma-van Loon JH, et al.Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement[J]. Leuk Lymphoma, 2017, 29:1-4. http://europepmc.org/abstract/MED/28849690
    [33] Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)[J]. Ann Oncol, 2007, 18:149-157. doi:  10.1093/annonc/mdl327
    [34] Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas:incidence, risk factors and therapeutic options[J]. Hematol Oncol, 2016, 27:61-70. doi:  10.1002/hon.881
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (477) PDF downloads(141) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return